“According to clinical trial data published in the European Journal of Clinical Pharmacology, patients with a history of migraine headaches could suffer from a clinical deficiency of the endocannabinoid system.
It was reported by investigators at Italy’s University of Perugia, Department of Public Health that patients suffering from chronic migraines possessed “significantly lower” levels of the endogenous cannabinoids anandamide and 2-arachidonylglycerol (2-AG) in their platelets compared to age-matched controls.
“These data support the potential involvement of a dysfunctioning of the endocannabinoid and serotonergic systems in the pathology of chronic migraine and medication-overuse headaches,” researchers’ concluded.
A previous paper appearing in the journal Neuroendocrinology Letters similarly suggested that migraine, fibromyalgia, and other treatment-resistant conditions could be linked with dysfunctions in the endocannabinoid system, which is assumed to play an important role in the regulation of humans’ mood, appetite, skeletal development, motor coordination, digestion, and reproduction.
The study “Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels,” appeared in an issue of the European Journal of Clinical Pharmacology.”